Effect of selenium on microalbuminuria

Effect of selenium on microalbuminuria in patients with diabetic nephropathy, A randomized controlled clinical trial (open label)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015112825266N1

Enrollment

Registered

2016-03-31

Start date

2015-12-22

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Diabetic nephropathy

Interventions

Intervention 1: intervention(selenium,200micrograms/day ,For three months). Intervention 2: control:receive routine care.

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Type 2 diabetic patients (30-60 years old) who had medical records in Diabetes Research and Clinical Center and would like to participate in this study. Also these patients had microalbuminuria.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Infectious diseases, active urinary tract infection, heavy exercise and heart failure and other chronic diseases,patients with cognitive impairment that hinders cooperation with the medical team, taking multivitamins and antioxidants drugs

Design outcomes

Primary

Measure	Time frame
Urea. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: mg/dl.;Micro-albuminuria(Urine albumin-to-creatinine ratio). Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/g of creatinine.;Creatinine. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;FBS. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;Selenium. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/l.;HbA1C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Percent.;Cholesterol. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;Triglycerides. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;HDL-C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;LDL-C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.	—

Measure

Time frame

Urea. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: mg/dl.;Micro-albuminuria(Urine albumin-to-creatinine ratio). Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/g of creatinine.;Creatinine. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;FBS. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;Selenium. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/l.;HbA1C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Percent.;Cholesterol. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;Triglycerides. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;HDL-C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;LDL-C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFallah-Tafti Bahareh

Yazd Diabetes Research Center

baharefallah@gmail.com+98 35 3728 0217

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026